At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from KEYNOTE-010, a phase 2/3 study of pembrolizumab, anti-PD-1 antibody, versus docetaxel for patients with PD-L1-positive non-small cell lung cancer (NSCLC) who had disease progression after platinum-containing systemic therapy.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement